Back to rankings

BGM Group Ltd. (BGM)

NEGATIVE
HealthcareDrug Manufacturers - Specialty & GenericChina

Fundamental

~22

Price

$0.27

Market Cap

$100M

Part 1 · What the company is worth

Overview

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Limited financial data available (37% of metrics). Scores may not accurately reflect this company's fundamentals.

Balance Sheet & Liquidity

Revenue

$74M

Net Income

$-39M

Free Cash Flow

-

Total Equity

$742M

Total Liabilities

-

Current Ratio

1.24

Interest Coverage

-

Debt/EBITDA

-

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Pre-revenueOvervalued
For a company classified as Pre-revenue, the appropriate models don't have enough data. The value below comes from the generic methods, which are less reliable for this kind of business: read it as an order of magnitude, and look at the range rather than the single number.

Fair Value

$0.10

Current Price

$0.27

Margin of Safety

-165.0%

Fair Value Range

$0.08 - $0.13

Estimation Methods

Analyst price target:Not enough data to compute it
Discounted cash flow (DCF):$0.10
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):Not enough data to compute it
Justified P/B:Not applicable to this type of company
Dividend discount (Gordon):Not applicable to this type of company
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:Not applicable to this type of company
Revenue multiple:Not enough data to compute it

Valuation Metrics

P/E Ratio

-

ROE

-7.0%

P/B Ratio

0.15

P/FCF

31.32

Gross Margin

16.6%

ROIC

-1.8%

Profitability Radar

Value Creation (Economic Moat)

ROIC

-1.8%

WACC

14.5%

ROIC − WACC

-16.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (2)

  • P/B Ratio 0.15
  • Current Ratio

Failed (8)

  • Price CAGR -54.38%
  • ROIC -1.8%
  • Gross Margin 16.6%
  • P/FCF 31.32
  • DCF valuation (Overvalued)
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Piotroski F-Score 0/9

Unavailable (17)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Debt/Equity ratio
  • Operating Margin NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Share Dilution (need 2+ years)
  • Net Margin Trend (invalid data)

Piotroski F-Score

0/9

Serious financial concerns

score
criteria

Earnings Quality

-

Low quality: investigate accounting

Share Dilution

-

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.